Alternative therapies in patients with non-muscle invasive bladder cancer

Sanli O., Lotan Y.

TURKISH JOURNAL OF UROLOGY, cilt.40, sa.4, ss.414-424, 2017 (ESCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 40 Konu: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5152/tud.2017.64624
  • Sayfa Sayıları: ss.414-424


Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guerin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required. Furthermore, intravesical BCG may be contraindicated in or untolerated by a group of patients. For these patients, some treatment options are readily available and a variety of them are currently under clinical investigation. In this review, these alternative therapies have been summarized.